Abstract Search

ea0052p14 | (1) | UKINETS2017

Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

Horsch D , Kulke MH , Caplin M , Anthony L , Bergsland E , Oberg K , Warner R , Kunz P , Pulido E Grande , Valle J , Dillon J , Lapuerta P , Banks P , Jackson S , Pavel M

Background: The phase III, placebo-controlled, randomized TELESTAR study evaluated efficacy and safety of telotristat ethyl (TE) in patients (pts) with diarrhoea (≥4 bowel movements (BMs)/day) due to carcinoid syndrome (CS) inadequately controlled by somatostatin analogs (SSAs). TE, a tryptophan hydroxylase inhibitor, decreases peripheral serotonin levels. As add-on treatment to SSAs, TE 250 mg 3x/day (tid) and TE 500 mg tid significantly reduced BM frequency (P...

0 shares

ea0046oc3 | (1) | UKINETS2016

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Horsch D , Kulke M , Caplin M , Anthony L , Bergsland E , Oberg K , Welin S , Warner R , Lombard-Bohas C , Kunz P , Valle J , Fleming D , Lapuerta P , Banks P , Pavel M

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...

0 shares

ea0094oc4.1 | Reproductive Endocrinology | SFEBES2023

Unsupervised steroid metabolome cluster analysis to dissect androgen excess and metabolic dysfunction in 488 women with polycystic ovary syndrome – results from the prospective DAISy-PCOS study

Melson Eka , Rocha Thais P. , Veen Roland J. , Abdi Lida , McDonnell Tara , Tandl Veronika , Hawley James M. , Wittemans Laura B. L. , Anthony Amarah V. , Gilligan Lorna C. , Shaheen Fozia , Kempegowda Punith , Gillett Caroline D.T. , Cussen Leanne , Missbrenner Cornelia , Lajeunesse-Trempe Fannie , Gleeson Helena , Rees Aled , Robinson Lynne , Jayasena Channa , Randeva Harpal S. , Dimitriadis Georgios K. , Gomes Larissa G. , J. Sitch Alice , Vradi Eleni , Obermayer-Pietsch Barbara , O'Reilly Michael W. , Taylor Angela E. , Biehl Michael , Arlt Wiebke

Introduction: Polycystic ovary syndrome (PCOS) affects 10% of women and is associated with a 2-3fold risk of type 2 diabetes (T2D), hypertension, fatty liver and cardiovascular disease. Androgen excess has been implicated as a major contributor to metabolic risk in PCOS. We aimed to identify PCOS sub-types with distinct androgen profiles and compare their cardiometabolic risk.Methods: We cross-sectionally studied 488 tre...

0 shares

Endocrine Abstracts

Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Unsupervised steroid metabolome cluster analysis to dissect androgen excess and metabolic dysfunction in 488 women with polycystic ovary syndrome – results from the prospective DAISy-PCOS study

BiosciAbstracts